255 related articles for article (PubMed ID: 16988931)
1. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features.
Buttitta F; Barassi F; Fresu G; Felicioni L; Chella A; Paolizzi D; Lattanzio G; Salvatore S; Camplese PP; Rosini S; Iarussi T; Mucilli F; Sacco R; Mezzetti A; Marchetti A
Int J Cancer; 2006 Dec; 119(11):2586-91. PubMed ID: 16988931
[TBL] [Abstract][Full Text] [Related]
2. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
[TBL] [Abstract][Full Text] [Related]
3. A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis.
Sartori G; Cavazza A; Bertolini F; Longo L; Marchioni A; Costantini M; Barbieri F; Migaldi M; Rossi G
Am J Clin Pathol; 2008 Feb; 129(2):202-10. PubMed ID: 18208799
[TBL] [Abstract][Full Text] [Related]
4. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.
Li C; Fang R; Sun Y; Han X; Li F; Gao B; Iafrate AJ; Liu XY; Pao W; Chen H; Ji H
PLoS One; 2011; 6(11):e28204. PubMed ID: 22140546
[TBL] [Abstract][Full Text] [Related]
5. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
Willmore-Payne C; Holden JA; Layfield LJ
Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
Shigematsu H; Lin L; Takahashi T; Nomura M; Suzuki M; Wistuba II; Fong KM; Lee H; Toyooka S; Shimizu N; Fujisawa T; Feng Z; Roth JA; Herz J; Minna JD; Gazdar AF
J Natl Cancer Inst; 2005 Mar; 97(5):339-46. PubMed ID: 15741570
[TBL] [Abstract][Full Text] [Related]
7. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains.
Li C; Sun Y; Fang R; Han X; Luo X; Wang R; Pan Y; Hu H; Zhang Y; Pao W; Shen L; Ji H; Chen H
J Thorac Oncol; 2012 Jan; 7(1):85-9. PubMed ID: 22071781
[TBL] [Abstract][Full Text] [Related]
8. [Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].
Sun LN; Luan HL; Zang FL; Wang M; Dong N; Guo Y; Sun BC; Zhan ZL
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):667-70. PubMed ID: 21122380
[TBL] [Abstract][Full Text] [Related]
9. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Arcila ME; Chaft JE; Nafa K; Roy-Chowdhuri S; Lau C; Zaidinski M; Paik PK; Zakowski MF; Kris MG; Ladanyi M
Clin Cancer Res; 2012 Sep; 18(18):4910-8. PubMed ID: 22761469
[TBL] [Abstract][Full Text] [Related]
10. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
Sun Y; Ren Y; Fang Z; Li C; Fang R; Gao B; Han X; Tian W; Pao W; Chen H; Ji H
J Clin Oncol; 2010 Oct; 28(30):4616-20. PubMed ID: 20855837
[TBL] [Abstract][Full Text] [Related]
11. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas.
Soung YH; Lee JW; Kim SY; Seo SH; Park WS; Nam SW; Song SY; Han JH; Park CK; Lee JY; Yoo NJ; Lee SH
Virchows Arch; 2005 May; 446(5):483-8. PubMed ID: 15815931
[TBL] [Abstract][Full Text] [Related]
12. Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras.
Takamochi K; Oh S; Matsuoka J; Suzuki K
Lung Cancer; 2012 Mar; 75(3):313-20. PubMed ID: 22209037
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung.
Sakuma Y; Matsukuma S; Yoshihara M; Nakamura Y; Nakayama H; Kameda Y; Tsuchiya E; Miyagi Y
Mod Pathol; 2007 Sep; 20(9):967-73. PubMed ID: 17618248
[TBL] [Abstract][Full Text] [Related]
14. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.
Zhang Y; Sun Y; Pan Y; Li C; Shen L; Li Y; Luo X; Ye T; Wang R; Hu H; Li H; Wang L; Pao W; Chen H
Clin Cancer Res; 2012 Apr; 18(7):1947-53. PubMed ID: 22317764
[TBL] [Abstract][Full Text] [Related]
15. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.
Arcila ME; Nafa K; Chaft JE; Rekhtman N; Lau C; Reva BA; Zakowski MF; Kris MG; Ladanyi M
Mol Cancer Ther; 2013 Feb; 12(2):220-9. PubMed ID: 23371856
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.
Boldrini L; Alì G; Gisfredi S; Ursino S; Baldini E; Melfi F; Lucchi M; Comin CE; Maddau C; Tibaldi C; Camacci T; Servadio A; Mussi A; Fontanini G
Oncol Rep; 2009 Oct; 22(4):683-91. PubMed ID: 19724844
[TBL] [Abstract][Full Text] [Related]
17. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
[TBL] [Abstract][Full Text] [Related]
18. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.
Marchetti A; Martella C; Felicioni L; Barassi F; Salvatore S; Chella A; Camplese PP; Iarussi T; Mucilli F; Mezzetti A; Cuccurullo F; Sacco R; Buttitta F
J Clin Oncol; 2005 Feb; 23(4):857-65. PubMed ID: 15681531
[TBL] [Abstract][Full Text] [Related]
19. EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition.
Rotella V; Fornaro L; Vasile E; Tibaldi C; Boldrini L; Chella A; D'Incecco A; Cirigliano G; Chioni A; Lupi C; Sensi E; Ginocchi L; Giovannelli S; Pennucci MC; Fontanini G; Baldini E
J Exp Clin Cancer Res; 2014 Oct; 33(1):77. PubMed ID: 25300933
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma.
Shan L; Qiu T; Ling Y; Guo L; Zheng B; Wang B; Li W; Li L; Ying J
PLoS One; 2015; 10(6):e0130447. PubMed ID: 26102513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]